[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"herpse-zoster\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:herpse-zoster":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":4},"100650849","early-phase-1-a-study-on-the-live-attenuated-herpes-zoster-vaccine-for-sequential-booster-immunization-following-recombinant-herpes-zoster-vaccine-100650849",false,"NCT07753265","A Study on the Live-Attenuated Herpes Zoster Vaccine for Sequential Booster Immunization Following Recombinant Herpes Zoster Vaccine","Inclusion Criteria:\n\n* Age ≥ 50 years old;\n* The participant can provide personal informed consent and sign the informed consent form;\n* temperature ≤ 37.0℃ on the day of administration;\n* capable of complying with the requirements of the clinical trial protocol to complete the trial.\n\nExclusion Criteria:\n\n* Subjects with immunodeficiency or immunosuppression caused by underlying diseases or treatments, including primary\u002Facquired immunodeficiency (e.g., AIDS and other virus-induced immunodeficiency), hematologic malignancies (leukemia, lymphoma or other bone marrow\u002Flymphoid neoplasms), ongoing immunosuppressive therapy, or radiotherapy\u002Fchemotherapy for malignancies.\n* Subjects with a history of allergic reaction to any component of the investigational product.\n* Subjects with acute infection or acute exacerbation of chronic infection (vaccination should be deferred).\n* Women of non-postmenopausal status with positive pregnancy test, pregnant or lactating women, or those planning pregnancy within 6 months.\n* Subjects with prior history of herpes zoster.\n* Subjects with prior receipt of varicella or herpes zoster vaccine.\n* Receipt of live-attenuated vaccines within 14 days, or subunit\u002Finactivated vaccines within 7 days prior to study vaccination.\n* Receipt of whole-blood, plasma or immunoglobulin within 5 months before, or within 3 weeks after study vaccination.\n* Receipt of investigational drugs from other clinical trials within 1 month before study vaccination, current participation in another clinical trial, or planned use of investigational agents during study period.\n* Current or planned use of salicylates (including aspirin, diflunisal, etc.).\n* Uncontrolled abnormal blood pressure at screening (systolic blood pressure ≥160 mmHg and\u002For diastolic blood pressure ≥100 mmHg despite medication).\n\nSubjects meeting contraindications or precautions specified in the product's prescribing information.\n\n* Any condition that, in the Investigator's opinion, may interfere with study evaluations.",true,"ALL","50 Years",{"count":19,"type":20},100,"ESTIMATED","INTERVENTIONAL",[23],"EARLY_PHASE1","Evaluate the immunogenicity after boost vaccination with the live attenuated herpes zoster vaccine.",[26],"Herpse Zoster","NOT_YET_RECRUITING","2026-08-04",{"date":30,"type":31},"2026-08-07","ACTUAL",{"date":33,"type":20},"2026-08-13",{"date":35,"type":20},"2026-09-20",{"name":37,"class":38},"Changchun BCHT Biotechnology Co.","INDUSTRY"]